Astrazeneca PLC (NYSE:AZN) – Analysts at Jefferies Group issued their Q3 2016 earnings per share (EPS) estimates for Astrazeneca PLC in a research report issued on Thursday. Jefferies Group analyst J. Holford anticipates that the firm will post earnings per share of $0.51 for the quarter. Jefferies Group currently has a “Buy” rating on the stock. Jefferies Group also issued estimates for Astrazeneca PLC’s FY2018 earnings at $2.37 EPS, FY2019 earnings at $2.85 EPS and FY2020 earnings at $3.41 EPS.
Astrazeneca PLC (NYSE:AZN) last issued its earnings results on Thursday, July 28th. The company reported $0.83 EPS for the quarter, beating the Zacks’ consensus estimate of $0.76 by $0.07. The business earned $5.60 billion during the quarter, compared to analysts’ expectations of $5.56 billion. Astrazeneca PLC had a net margin of 9.23% and a return on equity of 28.02%. The company’s quarterly revenue was down 4.0% compared to the same quarter last year. During the same period in the prior year, the business earned $1.21 earnings per share.
A number of other equities analysts have also weighed in on AZN. Shore Capital reiterated a “hold” rating on shares of Astrazeneca PLC in a research report on Wednesday, August 10th. Citigroup Inc. reiterated a “buy” rating on shares of Astrazeneca PLC in a research report on Wednesday, July 27th. Beaufort Securities restated a “hold” rating on shares of Astrazeneca PLC in a research report on Thursday, August 11th. JPMorgan Chase & Co. restated a “neutral” rating on shares of Astrazeneca PLC in a research report on Monday, August 8th. Finally, Piper Jaffray Cos. assumed coverage on shares of Astrazeneca PLC in a research report on Friday, September 23rd. They set an “overweight” rating on the stock. Three research analysts have rated the stock with a sell rating, nine have given a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $37.56.
Shares of Astrazeneca PLC (NYSE:AZN) opened at 30.59 on Friday. The firm has a market capitalization of $77.39 billion, a PE ratio of 34.96 and a beta of 0.75. The company’s 50-day moving average is $32.87 and its 200 day moving average is $30.88. Astrazeneca PLC has a 52-week low of $26.97 and a 52-week high of $35.04.
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Dodge & Cox increased its position in Astrazeneca PLC by 121.2% in the first quarter. Dodge & Cox now owns 26,049,650 shares of the company’s stock worth $733,558,000 after buying an additional 14,272,518 shares in the last quarter. Forester Capital Management LTD increased its position in Astrazeneca PLC by 68.4% in the first quarter. Forester Capital Management LTD now owns 3,200 shares of the company’s stock worth $109,000 after buying an additional 1,300 shares in the last quarter. Chubb Ltd. bought a new position in Astrazeneca PLC during the first quarter worth approximately $14,080,000. Primecap Management Co. CA increased its position in Astrazeneca PLC by 1,223.1% in the first quarter. Primecap Management Co. CA now owns 13,084,275 shares of the company’s stock worth $368,453,000 after buying an additional 12,095,375 shares in the last quarter. Finally, Stockman Asset Management increased its position in Astrazeneca PLC by 11.3% in the first quarter. Stockman Asset Management now owns 62,700 shares of the company’s stock worth $1,766,000 after buying an additional 6,380 shares in the last quarter. 11.39% of the stock is owned by institutional investors.
Astrazeneca PLC Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with MarketBeat.com's FREE daily email newsletter.